

## Publications

---

Production scientifique des membres de l'équipe depuis 2005 (EA 6295 depuis 2012) :

### Publications sur HAL

---

[2018](#)

[2017](#)

[2016](#)

### Publications 2014-2015

---

### Publications 2012-2013

---

### Publications 2005-2011

---

### Thèses

---

### Publications 2016

---

- E. Allard-Vannier, K. Hervé-Aubert, K. Kaaki, T. Blondy, A. Shebanova, K.V. Shaitan, A.A. Ignatova, M.L. Saboungi, A.V. Feofanov, I. Chourpa

*Folic acid-capped PEGylated magnetic nanoparticles enter cancer cells mostly via clathrin-dependent endocytosis.*  
BBA - General Subjects. 2016. doi: 10.1016/j.bbagen.2016.11.045

- F. Bonnier, G. Brachet, R. Duong, T. Sojinrin, R. Respaud, N. Aubrey, M.J. Baker, H.J. Byrne, I. Chourpa

*Screening the low molecular weight fraction of human serum using ATR-IR spectroscopy.*  
J Biophotonics. 2016, 9(10):1085-1097. doi: 10.1002/jbio.201600015

- H.J. Byrne, P. Knief, M.E. Keating, F. Bonnier

*Spectral pre and post processing for infrared and Raman spectroscopy of biological tissues and cells.*  
Chem Soc Rev. 2016, 45(7): 1865-1878. doi: 10.1039/c5cs00440c IF 34

- H.T.P. Nguyen, E. Allard-Vannier, C. Gaillard, I. Eddaoudi, L. Miloudi, M. Soucé, I. Chourpa, E. Munnier

*On the interaction of alginate-based core-shell nanocarriers with keratinocytes in vitro.*  
Colloids Surf B Biointerfaces. 2016, 142: 272-80. doi:10.1016/j.colsurfb.2016.02.055 IF 4,4

- A. Gambade, S. Zreika, M. Guéguinou, I. Chourpa, G. Fromont-Hankard, A.M. Bouchet, J. Burlaud-Gaillard, M. Potier-Cartereau, S. Roger, V. Aucagne, S. Chevalier, C. Vandier, C. Goupille, G. Weber

*Activation of TRPV2 and BKCa channels by the LL-37 enantiomers stimulates calcium entry and migration of cancer cells.*  
Oncotarget. 2016, doi: 10.18632/oncotarget.8122 IF 6,3

- C. Alric, N. Aubrey, E. Allard-Vannier, A. di Tommaso, T. Blondy, I. Dimier-Poisson, I. Chourpa, K. Hervé-Aubert

*Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanopropes for immunotargeting of breast cancer cells.*  
RSC Adv. 2016, 6, 37099-37109. doi: 10.1039/C6RA06076E IF 3,8

- R. Respaud, D. Marchand, T. Pelat, K.-M. Tchou-Wong, C.J. Roy, C. Parent, M. Cabrera, J. Guillemain, R. Mac Loughlin, E. Levacher, A. Fontayne, L. Douziech-Eyrolles, A. Junqua-Moulet, L. Guillemainault, P. Thullier, E. Guillot-Combe, L. Vecellio, N. Heuzé-Vourc'h.

*Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin.*  
J Control Release. 2016, 234: 21-32. doi: 10.1016/j.jconrel.2016.05.018. IF 8.0

- H.T. Nguyen, E. Munnier, X. Perse, F. Vial, F. Yvergnaux, T. Perrier, M. Soucé, I. Chourpa

*Qualitative and Quantitative Study of the Potential of Lipid Nanocapsules of One Hundred Twenty Nanometers for the Topical Administration of Hydrophobic Molecules.*

J Pharm Sci. 2016 Aug 9. pii: S0022-3549(16)41523-6. doi: 10.1016/j.xphs.2016.06.025. IF 2,6

- Z. Farhane, F. Bonnier, M.A. Maher, J. Bryant, A. Casey, H.J. Byrne

*Differentiating responses of lung cancer cell lines to Doxorubicin exposure: in vitro Raman micro spectroscopy, oxidative stress and bcl-2 protein expression.*

J Biophotonics. 2016 Apr 18. doi: 10.1002/jbio.201600019. [Epub ahead of print] IF 3,8

- A. Casey, M. Gargotti, F. Bonnier, H.J. Byrne

*Chemotherapeutic efficiency of drugs in vitro: Comparison of doxorubicin exposure in 3D and 2D culture matrices.*

Toxicol In Vitro. 2016, 33: 99-104. doi: 10.1016/j.tiv.2016.02.022. Epub 2016 Feb 27. IF 3,3